You are viewing: South Korea Human Organoids Market analysis
Part of: Human Organoids Market (Global)

The South Korea Human Organoids Market was valued at $4.8 Million in 2024 and projected to reach to $9 Million by 2029, representing a compound annual growth rate of 13.1%. South Korea's human organoids market is positioned for accelerated expansion through 2029, driven by increasing investments in regenerative medicine and a highly skilled scientific workforce.

South Korea Human Organoids Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Human Organoids Market Trends and Insights

  • This 13.1% compound annual growth rate reflects South Korea's strong commitment to regenerative medicine and advanced biotech research.
  • South Korea's leadership in biotechnology innovation, coupled with substantial government funding and a highly skilled workforce, positions the nation as a key player in organoid development and commercialization. The South Korea human organoids market is driven by increasing investment in personalized medicine, drug discovery applications, and disease modeling platforms.
  • South Korea's robust healthcare infrastructure and regulatory framework support the rapid adoption of organoid technologies across academic institutions and pharmaceutical companies.
  • By 2029, South Korea is expected to solidify its position as a regional hub for organoid research and therapeutic development, with expanding applications in regenerative medicine and precision healthcare..

Key Market Statistics

  • CAGR (2024-2029) 13.1% CAGR
  • Market Size, 2024 ~USD 4.8 Million
  • Forecast, 2029 ~USD 9 Million
  • Country South Korea

South Korea Human Organoids Market Overview

Market Valuation & Growth :

South Korea's human organoids market reached $4.8 million in 2024 and is projected to grow to $9.0 million by 2029, representing a robust 13.1% CAGR, demonstrating strong investor confidence in the sector.

Government Support & Funding :

South Korea's government has prioritized regenerative medicine through substantial R&D investments and biotech initiatives, creating a favorable ecosystem for organoid research and commercialization.

Biotech Innovation Leadership :

South Korea maintains a competitive edge in biotechnology innovation with advanced research facilities, skilled workforce, and strategic partnerships between academia and industry driving organoid development.

Regulatory Environment :

South Korea's progressive regulatory framework for regenerative medicine and cell-based therapies facilitates faster approval pathways, enabling quicker market entry for organoid-based products and solutions.

South Korea Human Organoids Market Dynamics

  • The country's biotechnology sector continues to attract both domestic and international funding, with organoids gaining prominence in drug discovery, disease modeling, and personalized medicine applications.
  • South Korea's strategic focus on advanced healthcare solutions and stem cell research creates substantial opportunities for market players.
  • The convergence of government support, academic excellence, and private sector innovation is expected to sustain the 13.1% CAGR, establishing South Korea as a regional hub for organoid technology development and commercialization..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • South Korea's human organoids market is valued at $4.8 million in 2024 and is forecast to reach $9.0 million by 2029, representing a 13.1% CAGR.
    • South Korea's advanced biotech ecosystem and government support drive rapid adoption of organoid technologies for drug discovery and disease modeling.
    • South Korea's investment in personalized medicine and regenerative therapies positions the nation as a regional leader in organoid commercialization.
    • South Korea's regulatory framework and skilled research workforce enable accelerated development and clinical translation of organoid-based therapeutics.

    Human Organoids Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment DEVELOPMENTAL BIOLOGY (Application)
    Forecast Period 2024-2029
    Growth Rate CAGR of 14.4% from 2024 to 2029
    Largest Segment READY-TO-USE PRODUCTS (Type)
    Market Size Base Year (Billions) ~USD 1.19 (2024)
    Revenue Forecast (Billions) ~USD 2.33 (2029)
    Segments Covered Product, Type, Source, Culture Method, Disease Area, Application, End User

    South Korea Human Organoids Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Product

    • Colorectal Models
    • Heart Models
    • Kidney Models
    • Liver Models
    • Lung Models
    • Other Products
    • Pancreatic Models

    By Type

    • 2D Colorectal Models
    • 2D Heart Models
    • 2D Kidney Models
    • 2D Liver Models
    • 2D Lung Models
    • 2D Models (Other Products)
    • 2D Pancreatic Models
    • 3D Bioprinted Colorectal Models
    • 3D Bioprinted Heart Models
    • 3D Bioprinted Kidney Models
    • 3D Bioprinted Liver Models
    • 3D Bioprinted Lung Models
    • 3D Bioprinted Models (Other Products)
    • 3D Bioprinted Pancreatic Models
    • 3D Colorectal Models
    • 3D Heart Models
    • 3D Kidney Models
    • 3D Liver Models
    • 3D Lung Models
    • 3D Models (Other Products)
    • 3D Pancreatic Models
    • Colorectal Organoids
    • Colorectal Spheroids
    • Cryopreserved Cells (Other Products)
    • Cryopreserved Colorectal Cells
    • Cryopreserved Heart Cells
    • Cryopreserved Hepatocytes
    • Cryopreserved Kidney Cells
    • Cryopreserved Lung Cells
    • Cryopreserved Pancreatic Cells
    • Customizable Products
    • Fresh Cells (Other Products)
    • Fresh Colorectal Cells
    • Fresh Heart Cells
    • Fresh Hepatocytes
    • Fresh Kidney Cells
    • Fresh Lung Cells
    • Fresh Pancreatic Cells
    • Heart Organoids
    • Heart Spheroids
    • Kidney Organoids
    • Kidney Spheroids
    • Liver Organoids
    • Liver Spheroids
    • Liver-On-A-Chip
    • Lung Organoids
    • Lung Spheroids
    • Organoids (Other Products)
    • Other 2D Colorectal Models
    • Other 2D Heart Models
    • Other 2D Kidney Models
    • Other 2D Liver Models
    • Other 2D Lung Models
    • Other 2D Models (Other Products)
    • Other 2D Pancreas Models
    • Other 3D Colorectal Models
    • Other 3D Heart Models
    • Other 3D Kidney Models
    • Other 3D Liver Models
    • Other 3D Lung Models
    • Other 3D Models (Other Products)
    • Other 3D Pancreatic Models
    • Pancreatic Organoids
    • Pancreatic Spheroids
    • Ready-To-Use Products
    • Spheroids (Other Products)

    By Source

    • Adult Stem Cells
    • Escs
    • Ipscs
    • Other Sources

    By Culture Method

    • 3D Bioprinting Culture
    • Air-Liquid Interface Culture
    • Matrigel Matrix Culture
    • Other Culture Methods
    • Suspension Culture

    By Disease Area

    • Cardiovascular Diseases
    • Gastrointestinal Diseases
    • Infectious Diseases
    • Liver Diseases
    • Neurological Disorders
    • Oncology
    • Other Disease Areas

    By Application

    • Developmental Biology
    • Disease Pathology
    • Drug Toxicity & Efficacy Testing
    • Other Applications
    • Personalized Medicine
    • Regenerative Medicine

    By End User

    • Academic & Research Institutes
    • Cros
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    Target Audience

    • Biotech & Pharmaceutical Companies : South Korea-focused biotech firms and pharmaceutical companies need market intelligence to develop organoid-based products, identify partnerships, and optimize commercialization strategies in this growing market.
    • Research Institutions & Universities : Academic centers and research organizations in South Korea require market data to secure funding, benchmark their organoid research capabilities, and align initiatives with commercial opportunities.
    • Government & Policy Makers : South Korean government agencies and policy bodies need market insights to inform regenerative medicine strategies, allocate R&D budgets, and strengthen the nation's biotech competitiveness.
    • Investors & Venture Capitalists : Investment firms targeting South Korea's biotech sector require detailed market analysis to identify promising organoid companies, assess growth potential, and make informed funding decisions.
    • Healthcare & Medical Device Companies : Healthcare providers and medical device manufacturers need South Korea market data to explore organoid integration into clinical applications, diagnostics, and personalized treatment solutions.

    Reasons to Buy this Report

    • Market-Specific Growth Projections : Access detailed forecasts for South Korea's organoids market through 2029, enabling strategic planning and investment decisions tailored to this high-growth Asian biotech market.
    • Competitive Landscape Analysis : Understand South Korea's unique competitive dynamics, key players, and market positioning within the broader Asia-Pacific organoid sector to identify partnership and investment opportunities.
    • Regulatory & Policy Insights : Gain comprehensive knowledge of South Korea's regenerative medicine regulations, government incentives, and approval pathways to navigate market entry and commercialization strategies effectively.
    • Technology & Innovation Trends : Discover cutting-edge organoid applications in South Korean research institutions and biotech companies, including drug discovery, disease modeling, and personalized medicine developments.
    • Investment & Funding Opportunities : Identify government funding programs, venture capital trends, and strategic partnerships within South Korea's biotech ecosystem to support business expansion and R&D initiatives.

    Frequently asked questions

    What is the current size of South Korea's human organoids market?

    South Korea's human organoids market was valued at $4.8 million in 2024 and is projected to grow to $9.0 million by 2029.

    What is the expected growth rate for South Korea's organoids market?

    South Korea's human organoids market is expected to grow at a compound annual growth rate (CAGR) of 13.1% from 2024 to 2029.

    What factors are driving growth in South Korea's organoids market?

    South Korea's organoids market growth is driven by increased investment in personalized medicine, drug discovery applications, disease modeling, government funding, and a highly skilled biotech workforce.

    How does South Korea's organoids market compare to the global market?

    South Korea's 13.1% CAGR is slightly below the global average of 14.4%, reflecting strong regional performance while maintaining alignment with worldwide market trends.

    What applications are most prominent in South Korea's organoids market?

    South Korea's organoids market is primarily focused on drug discovery, disease modeling, personalized medicine, and regenerative medicine applications across academic and pharmaceutical sectors.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Human Organoids Market

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME DESIGNATION
    Thermo Fisher Scientific Inc. Director of sales
    Merck KGaA Sales Executive

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the human organoids market have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    The research methodology used to estimate the market size includes the following:

    Human Organoids Market

    Data Triangulation

    After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.

    Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department  
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global human organoids market, by product, source, type, culture method, disease area, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall human organoids market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and GCC Countries
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

     

    Get the Full Human Organoids Market Report

    Full forecast, segment splits, and company analysis for all Human Organoids Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status